Literature DB >> 10532198

Intraperitoneal chemotherapy.

M Markman1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10532198     DOI： 10.1016/s1040-8428(99)00017-7

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  7 in total

Review 1.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  Kenneth Jaaback; Nick Johnson; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules.

Authors:  Kota Yamashita; Shigeru Tsunoda; Shutaro Gunji; Takahide Murakami; Takahisa Suzuki; Yasuhiko Tabata; Yoshiharu Sakai
Journal:  Surg Today       Date:  2019-03-07       Impact factor: 2.549

Review 3.  Intraperitoneal drug delivery of antineoplastics.

Authors:  M Markman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Intraperitoneal therapy for peritoneal cancer.

Authors:  Ze Lu; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

5.  Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.

Authors:  Maurie Markman; Mark Brady; Alan Hutson; Jonathan S Berek
Journal:  Int J Gynecol Cancer       Date:  2009-02       Impact factor: 3.437

Review 6.  Pharmaceutical management of ovarian cancer : current status.

Authors:  Maurie Markman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Polymeric Gd-DOTA amphiphiles form spherical and fibril-shaped nanoparticle MRI contrast agents.

Authors:  Lyndsay M Randolph; Clare L M LeGuyader; Michael E Hahn; Christopher M Andolina; Joseph P Patterson; Robert F Mattrey; Jill E Millstone; Mauro Botta; Miriam Scadeng; Nathan C Gianneschi
Journal:  Chem Sci       Date:  2016-03-22       Impact factor: 9.825
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.